Social Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry
2022; Lippincott Williams & Wilkins; Volume: 15; Issue: 11 Linguagem: Inglês
10.1161/circheartfailure.122.010022
ISSN1941-3297
Autores Tópico(s)Advanced battery technologies research
ResumoHomeCirculation: Heart FailureVol. 15, No. 11Social Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextSocial Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry Michelle M. Kittleson Michelle M. KittlesonMichelle M. Kittleson https://orcid.org/0000-0003-4492-2691 Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA. Originally published15 Nov 2022https://doi.org/10.1161/CIRCHEARTFAILURE.122.010022Circulation: Heart Failure. 2022;15FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 1009.https://www.ahajournals.org/journal/circheartfailureReferences1. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure.JAMA. 2009; 302:1658–1665. doi: 10.1001/jama.2009.1493CrossrefMedlineGoogle Scholar2. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, Yancy CW, Albert NM, Peterson ED. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure.JAMA. 2007; 298:1525–1532. doi: 10.1001/jama.298.13.1525CrossrefMedlineGoogle Scholar3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.N Engl J Med. 1999; 341:709–717. doi: 10.1056/NEJM199909023411001CrossrefMedlineGoogle Scholar4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med. 2003; 348:1309–1321. doi: 10.1056/NEJMoa030207CrossrefMedlineGoogle Scholar5. Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.JAMA. 2012; 308:2097–2107. doi: 10.1001/jama.2012.14795CrossrefMedlineGoogle Scholar6. Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, et al. Kidney function and outcomes in patients hospitalized with heart filure.J Am Coll Cardiol. 2021; 78:330–343. doi: 10.1016/j.jacc.2021.05.002CrossrefMedlineGoogle Scholar7. Pandey A, Golwala H, Xu H, DeVore AD, Matsouaka R, Pencina M, Kumbhani DJ, Hernandez AF, Bhatt DL, Heidenreich PA, et al. Association of 30-day readmission metric for heart failure under the hospital readmissions reduction program with quality of care and outcomes.JACC Heart Fail. 2016; 4:935–946. doi: 10.1016/j.jchf.2016.07.003CrossrefMedlineGoogle Scholar8. Gupta A, Allen LA, Bhatt DL, Cox M, DeVore AD, Heidenreich PA, Hernandez AF, Peterson ED, Matsouaka RA, Yancy CW, et al. Association of the hospital readmissions reduction program implementation with readmission and mortality outcomes in heart failure.JAMA Cardiol. 2018; 3:44–53. doi: 10.1001/jamacardio.2017.4265CrossrefMedlineGoogle Scholar9. Li Y, Wang H, Luo Y. Improving fairness in the prediction of heart failure length-of-stay and mortality by integrating social determinants of health.Circ Heart Fail. 2022; 15:xxx. doi: 10.1161/CIRCHEARTFAILURE.122.009473LinkGoogle Scholar10. Segar MW, Keshvani N, Rao S, Fonarow GC, Das SR, Pandey A. Race, social determinants of health, and length of stay among hospitalized patients with heart failure: an analysis from the Get With The Guidelines-Heart Failure registry.Circ Heart Fail. 2022; 15:xxx. doi: 10.1161/CIRCHEARTFAILURE.121.009401LinkGoogle Scholar11. Rao VN, Mentz RJ, Coniglio AC, Kelsey MD, Fudim M, Fonarow GC, Matsouaka RA, Devore AD, Caughey MC. Neighborhood socioeconomic disadvantage and hospitalized heart failure outcomes in the American Heart Association Get With The Guidelines-Heart Failure registry.Circ Heart Fail. 2022; 15:xxx. doi: 10.1161/CIRCHEARTFAILURE.121.009353LinkGoogle Scholar12. Zheng J, Tisdale RL, Heidenreich PA, Sandhu AT. Disparities in hospital length of stay across race and ethnicity among patients with heart failure.Circ Heart Fail. 2022; 15:xxx. doi: 10.1161/CIRCHEARTFAILURE.121.009362LinkGoogle Scholar13. Tran JS, Loveland MG, Alamer A, Piña IL, Sweitzer NK. Clinical and socioeconomic determinants of angiotensin receptor blocker-neprilysin inhibitor prescription at hospital discharge in patients with heart failure with reduced ejection fraction.Circ Heart Fail. 2022;15:1036–1047. doi: 10.1161/CIRCHEARTFAILURE.121.009395LinkGoogle Scholar14. Sandberg S. Lean in: women, work, and the will to lead. First edition. New York: Alfred A. Knopf, 2013. ©2013; 2013.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetails November 2022Vol 15, Issue 11 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIRCHEARTFAILURE.122.010022PMID: 36378754 Originally publishedNovember 15, 2022 Keywordsguidelinedirected medical therapyEditorialsdemographyheart failureregistryPDF download Advertisement SubjectsCardiomyopathyHeart Failure
Referência(s)